ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Juno Builds With X-Body Buy

by Lisa M. Jarvis
June 8, 2015 | APPEARED IN VOLUME 93, ISSUE 23

Juno Therapeutics has paid roughly $44 million in a mix of cash and stock to acquire X-Body, a Waltham, Mass.-based biotech firm with protein-engineering technology. Juno uses several different approaches to reengineer a patient’s own T cells to home in on and kill cancer cells. The X-Body purchase adds to a buying spree for Juno. In recent weeks, the Seattle-based firm shelled out $70 million for Germany’s Stage Cell Therapeutics, an expert in cellular therapy manufacturing, and paid $25 million up front to access Editas Medicine’s gene-editing capabilities.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment